These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Characterization of Spink6 in mouse skin: the conserved inhibitor of kallikrein-related peptidases is reduced by barrier injury. Fischer J; Wu Z; Kantyka T; Sperrhacke M; Dimitrieva O; Koblyakova Y; Ahrens K; Graumann N; Baurecht H; Reiss K; Schröder JM; Proksch E; Meyer-Hoffert U J Invest Dermatol; 2014 May; 134(5):1305-1312. PubMed ID: 24352040 [TBL] [Abstract][Full Text] [Related]
3. Isolation of SPINK6 in human skin: selective inhibitor of kallikrein-related peptidases. Meyer-Hoffert U; Wu Z; Kantyka T; Fischer J; Latendorf T; Hansmann B; Bartels J; He Y; Gläser R; Schröder JM J Biol Chem; 2010 Oct; 285(42):32174-81. PubMed ID: 20667819 [TBL] [Abstract][Full Text] [Related]
4. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor. Meyer-Hoffert U; Wu Z; Schröder JM PLoS One; 2009; 4(2):e4372. PubMed ID: 19190773 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of kallikrein-related peptidases by the serine protease inhibitor of Kazal-type 6. Kantyka T; Fischer J; Wu Z; Declercq W; Reiss K; Schröder JM; Meyer-Hoffert U Peptides; 2011 Jun; 32(6):1187-92. PubMed ID: 21439340 [TBL] [Abstract][Full Text] [Related]
6. Gingipains of Porphyromonas gingivalis Affect the Stability and Function of Serine Protease Inhibitor of Kazal-type 6 (SPINK6), a Tissue Inhibitor of Human Kallikreins. Plaza K; Kalinska M; Bochenska O; Meyer-Hoffert U; Wu Z; Fischer J; Falkowski K; Sasiadek L; Bielecka E; Potempa B; Kozik A; Potempa J; Kantyka T J Biol Chem; 2016 Sep; 291(36):18753-64. PubMed ID: 27354280 [TBL] [Abstract][Full Text] [Related]
7. Cross-linking of SPINK6 by transglutaminases protects from epidermal proteases. Fischer J; Koblyakova Y; Latendorf T; Wu Z; Meyer-Hoffert U J Invest Dermatol; 2013 May; 133(5):1170-7. PubMed ID: 23303447 [TBL] [Abstract][Full Text] [Related]
8. Expression, purification and characterization of recombinant human serine proteinase inhibitor Kazal-type 6 (SPINK6) in Pichia pastoris. Lu H; Huang J; Li G; Ge K; Wu H; Huang Q Protein Expr Purif; 2012 Mar; 82(1):144-9. PubMed ID: 22212898 [TBL] [Abstract][Full Text] [Related]
9. Regulation of kallikrein-related peptidases in the skin - from physiology to diseases to therapeutic options. Fischer J; Meyer-Hoffert U Thromb Haemost; 2013 Sep; 110(3):442-9. PubMed ID: 23446429 [TBL] [Abstract][Full Text] [Related]
10. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. Borgoño CA; Michael IP; Komatsu N; Jayakumar A; Kapadia R; Clayman GL; Sotiropoulou G; Diamandis EP J Biol Chem; 2007 Feb; 282(6):3640-52. PubMed ID: 17158887 [TBL] [Abstract][Full Text] [Related]
11. Physiological and pathological roles of kallikrein-related peptidases in the epidermis. Kishibe M J Dermatol Sci; 2019 Aug; 95(2):50-55. PubMed ID: 31279501 [TBL] [Abstract][Full Text] [Related]
12. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. Komatsu N; Takata M; Otsuki N; Ohka R; Amano O; Takehara K; Saijoh K J Invest Dermatol; 2002 Mar; 118(3):436-43. PubMed ID: 11874482 [TBL] [Abstract][Full Text] [Related]
13. Proteolytic processing of human growth hormone by multiple tissue kallikreins and regulation by the serine protease inhibitor Kazal-Type5 (SPINK5) protein. Komatsu N; Saijoh K; Otsuki N; Kishi T; Micheal IP; Obiezu CV; Borgono CA; Takehara K; Jayakumar A; Wu HK; Clayman GL; Diamandis EP Clin Chim Acta; 2007 Feb; 377(1-2):228-36. PubMed ID: 17140555 [TBL] [Abstract][Full Text] [Related]
15. Novel inhibitory activity for serine protease inhibitor Kazal type-3 (Spink3) on human recombinant kallikreins. Assis DM; Zalazar L; Juliano MA; De Castro R; Cesari A Protein Pept Lett; 2013 Oct; 20(10):1098-107. PubMed ID: 23590280 [TBL] [Abstract][Full Text] [Related]
16. Keratinocyte-specific mesotrypsin contributes to the desquamation process via kallikrein activation and LEKTI degradation. Miyai M; Matsumoto Y; Yamanishi H; Yamamoto-Tanaka M; Tsuboi R; Hibino T J Invest Dermatol; 2014 Jun; 134(6):1665-1674. PubMed ID: 24390132 [TBL] [Abstract][Full Text] [Related]